Reattogenicita e immunogenicita di un nuovo vaccino combinato anti morbillo-parotite-rosolia

Translated title of the contribution: Safety and immunogenicity of a new combined measles-mumps-rubella vaccine

G. Faldella, E. Marchiani, A. Di Comite, R. Alessandroni, A. Perrone, M. R. Sabatini, M. Massinissa, G. M. Magini, G. P. Salvioli

Research output: Contribution to journalArticle

Abstract

Premises: Universal childhood immunization against measles, mumps and rubella is recommended. Some doubt has arised on the efficacy of some vaccine strains due to their weak immunogenicity. Objective: To compare the safety, reactogenicity and immunogenicity of a new MMR vaccine (Priorix, Smithkline Beecham Biologicals) containing live attenuated Schwarz strain (Measles), Rit 4385 strain (Mumps), RA 27/3 strain (Rubella) and of an established reference and widely used in Italy vaccine (Triviraten, Berna) containing Edmonston- Zagreb strain (Measles), Rubini strain (Mumps), RA 27/3 strain (Rubella). Methods: A hundred and fifty-eight healthy children 12 to 24 month old were enrolled in a blinded, randomized study to receive a single dose of one of the two vaccines. Safety and reactogenicity were assessed by a solicited follow-up of local and general adverse experiences, performed by the parents of the vaccines, on the day of vaccination and during the 42 subsequent days. Immunogenicity was assessed by measuring the specific antibody levels against mumps, measles and rubella in two serum samples obtained before and 6 weeks after vaccination, using a commercial immunoassay kit. Results: Local and general reactions were mild without any significant difference between the two vaccines groups. The rates of seroconversion for measles, mumps, rubella were 98.5%, 98.5%, 100%, respectively, in Priorix group and 100%, 30%, 100%, respectively, in Triviraten group. Mean antibody geometric titres were significantly higher with Schwarz strain (2766 mUI/ml) than with Edmonston- Zagreb strain (836 mUI/ml) and with Rit 4385 strain (1697 mUI/ml) that with Rubini strain (183 mUI/ml). Conclusions: The new SB MMR vaccine seems well balanced in terms of tolerability and highly immunogenicity for all the three viral components.

Original languageItalian
Pages (from-to)313-317
Number of pages5
JournalRivista Italiana di Pediatria
Volume25
Issue number2
Publication statusPublished - 1999

Fingerprint

Measles-Mumps-Rubella Vaccine
Combined Vaccines
Mumps
Rubella
Measles
Vaccines
Safety
Vaccination
Viral Structures
Antibodies
Immunoassay
Italy
Immunization
Parents
Serum

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Faldella, G., Marchiani, E., Di Comite, A., Alessandroni, R., Perrone, A., Sabatini, M. R., ... Salvioli, G. P. (1999). Reattogenicita e immunogenicita di un nuovo vaccino combinato anti morbillo-parotite-rosolia. Rivista Italiana di Pediatria, 25(2), 313-317.

Reattogenicita e immunogenicita di un nuovo vaccino combinato anti morbillo-parotite-rosolia. / Faldella, G.; Marchiani, E.; Di Comite, A.; Alessandroni, R.; Perrone, A.; Sabatini, M. R.; Massinissa, M.; Magini, G. M.; Salvioli, G. P.

In: Rivista Italiana di Pediatria, Vol. 25, No. 2, 1999, p. 313-317.

Research output: Contribution to journalArticle

Faldella, G, Marchiani, E, Di Comite, A, Alessandroni, R, Perrone, A, Sabatini, MR, Massinissa, M, Magini, GM & Salvioli, GP 1999, 'Reattogenicita e immunogenicita di un nuovo vaccino combinato anti morbillo-parotite-rosolia', Rivista Italiana di Pediatria, vol. 25, no. 2, pp. 313-317.
Faldella G, Marchiani E, Di Comite A, Alessandroni R, Perrone A, Sabatini MR et al. Reattogenicita e immunogenicita di un nuovo vaccino combinato anti morbillo-parotite-rosolia. Rivista Italiana di Pediatria. 1999;25(2):313-317.
Faldella, G. ; Marchiani, E. ; Di Comite, A. ; Alessandroni, R. ; Perrone, A. ; Sabatini, M. R. ; Massinissa, M. ; Magini, G. M. ; Salvioli, G. P. / Reattogenicita e immunogenicita di un nuovo vaccino combinato anti morbillo-parotite-rosolia. In: Rivista Italiana di Pediatria. 1999 ; Vol. 25, No. 2. pp. 313-317.
@article{fceab12da6c34b55a901946dafda5468,
title = "Reattogenicita e immunogenicita di un nuovo vaccino combinato anti morbillo-parotite-rosolia",
abstract = "Premises: Universal childhood immunization against measles, mumps and rubella is recommended. Some doubt has arised on the efficacy of some vaccine strains due to their weak immunogenicity. Objective: To compare the safety, reactogenicity and immunogenicity of a new MMR vaccine (Priorix, Smithkline Beecham Biologicals) containing live attenuated Schwarz strain (Measles), Rit 4385 strain (Mumps), RA 27/3 strain (Rubella) and of an established reference and widely used in Italy vaccine (Triviraten, Berna) containing Edmonston- Zagreb strain (Measles), Rubini strain (Mumps), RA 27/3 strain (Rubella). Methods: A hundred and fifty-eight healthy children 12 to 24 month old were enrolled in a blinded, randomized study to receive a single dose of one of the two vaccines. Safety and reactogenicity were assessed by a solicited follow-up of local and general adverse experiences, performed by the parents of the vaccines, on the day of vaccination and during the 42 subsequent days. Immunogenicity was assessed by measuring the specific antibody levels against mumps, measles and rubella in two serum samples obtained before and 6 weeks after vaccination, using a commercial immunoassay kit. Results: Local and general reactions were mild without any significant difference between the two vaccines groups. The rates of seroconversion for measles, mumps, rubella were 98.5{\%}, 98.5{\%}, 100{\%}, respectively, in Priorix group and 100{\%}, 30{\%}, 100{\%}, respectively, in Triviraten group. Mean antibody geometric titres were significantly higher with Schwarz strain (2766 mUI/ml) than with Edmonston- Zagreb strain (836 mUI/ml) and with Rit 4385 strain (1697 mUI/ml) that with Rubini strain (183 mUI/ml). Conclusions: The new SB MMR vaccine seems well balanced in terms of tolerability and highly immunogenicity for all the three viral components.",
keywords = "Immunogenicity, Measles-mumps-rubella vaccine, Safety, Tolerability",
author = "G. Faldella and E. Marchiani and {Di Comite}, A. and R. Alessandroni and A. Perrone and Sabatini, {M. R.} and M. Massinissa and Magini, {G. M.} and Salvioli, {G. P.}",
year = "1999",
language = "Italian",
volume = "25",
pages = "313--317",
journal = "Rivista Italiana di Pediatria",
issn = "0392-5161",
publisher = "Pacini Editore s.r.l.",
number = "2",

}

TY - JOUR

T1 - Reattogenicita e immunogenicita di un nuovo vaccino combinato anti morbillo-parotite-rosolia

AU - Faldella, G.

AU - Marchiani, E.

AU - Di Comite, A.

AU - Alessandroni, R.

AU - Perrone, A.

AU - Sabatini, M. R.

AU - Massinissa, M.

AU - Magini, G. M.

AU - Salvioli, G. P.

PY - 1999

Y1 - 1999

N2 - Premises: Universal childhood immunization against measles, mumps and rubella is recommended. Some doubt has arised on the efficacy of some vaccine strains due to their weak immunogenicity. Objective: To compare the safety, reactogenicity and immunogenicity of a new MMR vaccine (Priorix, Smithkline Beecham Biologicals) containing live attenuated Schwarz strain (Measles), Rit 4385 strain (Mumps), RA 27/3 strain (Rubella) and of an established reference and widely used in Italy vaccine (Triviraten, Berna) containing Edmonston- Zagreb strain (Measles), Rubini strain (Mumps), RA 27/3 strain (Rubella). Methods: A hundred and fifty-eight healthy children 12 to 24 month old were enrolled in a blinded, randomized study to receive a single dose of one of the two vaccines. Safety and reactogenicity were assessed by a solicited follow-up of local and general adverse experiences, performed by the parents of the vaccines, on the day of vaccination and during the 42 subsequent days. Immunogenicity was assessed by measuring the specific antibody levels against mumps, measles and rubella in two serum samples obtained before and 6 weeks after vaccination, using a commercial immunoassay kit. Results: Local and general reactions were mild without any significant difference between the two vaccines groups. The rates of seroconversion for measles, mumps, rubella were 98.5%, 98.5%, 100%, respectively, in Priorix group and 100%, 30%, 100%, respectively, in Triviraten group. Mean antibody geometric titres were significantly higher with Schwarz strain (2766 mUI/ml) than with Edmonston- Zagreb strain (836 mUI/ml) and with Rit 4385 strain (1697 mUI/ml) that with Rubini strain (183 mUI/ml). Conclusions: The new SB MMR vaccine seems well balanced in terms of tolerability and highly immunogenicity for all the three viral components.

AB - Premises: Universal childhood immunization against measles, mumps and rubella is recommended. Some doubt has arised on the efficacy of some vaccine strains due to their weak immunogenicity. Objective: To compare the safety, reactogenicity and immunogenicity of a new MMR vaccine (Priorix, Smithkline Beecham Biologicals) containing live attenuated Schwarz strain (Measles), Rit 4385 strain (Mumps), RA 27/3 strain (Rubella) and of an established reference and widely used in Italy vaccine (Triviraten, Berna) containing Edmonston- Zagreb strain (Measles), Rubini strain (Mumps), RA 27/3 strain (Rubella). Methods: A hundred and fifty-eight healthy children 12 to 24 month old were enrolled in a blinded, randomized study to receive a single dose of one of the two vaccines. Safety and reactogenicity were assessed by a solicited follow-up of local and general adverse experiences, performed by the parents of the vaccines, on the day of vaccination and during the 42 subsequent days. Immunogenicity was assessed by measuring the specific antibody levels against mumps, measles and rubella in two serum samples obtained before and 6 weeks after vaccination, using a commercial immunoassay kit. Results: Local and general reactions were mild without any significant difference between the two vaccines groups. The rates of seroconversion for measles, mumps, rubella were 98.5%, 98.5%, 100%, respectively, in Priorix group and 100%, 30%, 100%, respectively, in Triviraten group. Mean antibody geometric titres were significantly higher with Schwarz strain (2766 mUI/ml) than with Edmonston- Zagreb strain (836 mUI/ml) and with Rit 4385 strain (1697 mUI/ml) that with Rubini strain (183 mUI/ml). Conclusions: The new SB MMR vaccine seems well balanced in terms of tolerability and highly immunogenicity for all the three viral components.

KW - Immunogenicity

KW - Measles-mumps-rubella vaccine

KW - Safety

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=0032730863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032730863&partnerID=8YFLogxK

M3 - Articolo

VL - 25

SP - 313

EP - 317

JO - Rivista Italiana di Pediatria

JF - Rivista Italiana di Pediatria

SN - 0392-5161

IS - 2

ER -